Integrated Biopharma, Inc. INBP

Company Overview

Integrated Biopharma, Inc. (NASDAQ: INBP) is a specialty health and wellness company focused on the manufacturing, distribution, and marketing of nutraceuticals, vitamins, minerals, supplements, and contract-manufactured health products. The company operates within the broader dietary supplements and consumer health industries, serving both branded consumer markets and private-label or contract manufacturing customers. Its revenue is primarily generated through the sale of nutritional supplements, over-the-counter wellness products, and manufacturing services for third-party brands.

The company’s operations have historically centered on vertically integrated supplement manufacturing and distribution capabilities. Integrated Biopharma evolved through acquisitions and consolidation of nutraceutical manufacturing and distribution businesses, with a strategic emphasis on quality-controlled production and specialized formulation expertise. Public filings indicate that the company has maintained a focus on both proprietary products and contract manufacturing relationships, positioning itself as a niche participant in the health supplement market.

Business Operations

Integrated Biopharma conducts business through operating subsidiaries involved in nutritional supplement manufacturing and distribution. Key operating entities historically associated with the company include Manhattan Drug Company, Inc., IFS International, Inc., and related supplement manufacturing operations. The company generates revenue through wholesale distribution, direct product sales, and manufacturing agreements with third-party supplement brands and retailers. Its activities include formulation development, encapsulation, packaging, labeling, and distribution of dietary supplements and wellness products.

The company’s operations are primarily concentrated in the United States, though products may reach international markets through distributors and commercial partners. Integrated Biopharma controls manufacturing and formulation capabilities that support both branded and private-label production. Public disclosures indicate that the company’s operational strategy has emphasized maintaining manufacturing infrastructure and leveraging industry relationships in the nutraceutical supply chain. Data regarding significant international joint ventures or large-scale strategic partnerships is inconclusive based on available public sources.

Strategic Position & Investments

Integrated Biopharma’s strategic direction has historically focused on sustaining and expanding its position in the nutritional supplement and wellness manufacturing sector. Growth initiatives have included operational restructuring, cost management, enhancement of manufacturing efficiencies, and the continued development of private-label and contract manufacturing relationships. The company has also pursued opportunities tied to increased consumer demand for wellness, preventive health, and nutritional supplementation products.

The company’s investments have largely centered on manufacturing capabilities, product development, and subsidiary operations rather than large-scale transformative acquisitions in recent years. Public filings reference ongoing efforts to strengthen operational performance and improve financial stability. Integrated Biopharma remains involved in sectors connected to dietary supplements, nutraceutical formulation, and health-focused consumer products. Data regarding material investments in emerging biotechnology, pharmaceutical development, or advanced health technologies is inconclusive based on available public sources.

Geographic Footprint

Integrated Biopharma is headquartered in the United States, with operational activities concentrated primarily in the domestic U.S. market. Its manufacturing, distribution, and administrative operations have historically been based in the northeastern United States. The company serves customers across multiple U.S. regions through wholesale, retail, and contract manufacturing channels.

While the company’s primary operational footprint remains domestic, certain products and distribution relationships may extend into international markets through export activity and third-party distributors. Publicly available information does not indicate a substantial direct operational presence across multiple continents comparable to larger multinational supplement companies. Data regarding extensive international manufacturing operations or foreign subsidiaries is inconclusive based on available public sources.

Leadership & Governance

Integrated Biopharma operates under a publicly traded corporate governance structure subject to U.S. securities regulations and reporting requirements, including disclosures contained in SEC filings such as annual reports and proxy statements. Leadership has historically emphasized operational continuity, manufacturing efficiency, and maintaining a presence in the competitive nutritional supplement market. Strategic priorities disclosed in public filings include operational optimization and long-term shareholder value preservation.

Key executives and leadership figures associated with the company include:

• Andrew R. Heyer – Chairman of the Board
• Drew Field – President and Chief Executive Officer
• Rochelle Chimenti – Chief Financial Officer

Founder information and historical executive leadership details vary across public records. Data regarding a formally articulated leadership philosophy beyond operational and financial objectives disclosed in regulatory filings is inconclusive based on available public sources.